Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and ...

The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during ...

Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in ...

Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday ...

Shares, though, were punished Monday after the drug maker said its blockbuster obesity treatment Wegovy failed to slow ...

The deal marks Healthify's first such partnership with a drugmaker, and it hopes similar agreements will boost its paid ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

In November, Mounjaro clocked Rs 108 crore in sales, making it the number 1 brand in the IPM, reflecting sustained momentum ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Wondering if Novo Nordisk is still worth buying after its huge run up in recent years, or if the best days are already priced in? You are not alone, and this is exactly what we are going to unpack.

Healthify plans to expand partnerships with weight-loss drugmakers, leveraging its new deal with Novo Nordisk to enhance ...